Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> In suspected CD, low serum iron and elevated CRP had a statistically significant association with CD diagnosis, being helpful to identify patients with higher CD probability before SBCE.
|
31378118 |
2019 |
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
<b>Conclusions:</b> Baseline CRP level and CRP reduction rate might be clinical predictors for PNR or LOR to anti-TNF in patients with CD, and could guide proper therapeutic interventions in patients with CD.
|
31303093 |
2019 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
<b>Results:</b> Following infliximab, FC and CRP declined (<i>p</i> < .0001) along with HBi for CD and pMCS for UC.
|
31499013 |
2019 |
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
84 bp allele of CTLA-4 (AT)n repeat polymorphism was associated with CD in central China. sCTLA-4 levels were highly expressed in CD, especially in active disease, and were correlated with CRP levels and disease behavior in CD patients.
|
21251066 |
2011 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Crohn's disease activity index (CDAI) and Simple Endoscopic Score for Crohn's disease (SES-CD) for Crohn's disease (CD) or Mayo score and ulcerative colitis endoscopic index of severity (UCEIS) for ulcerative colitis (UC), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were used to evaluate the disease activity.
|
30558634 |
2018 |
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Crohn's disease activity index (CDAI), Mayo score, C-reactive protein (CRP) level, and erythrocyte sedimentation rate (ESR) were measured.
|
31749597 |
2019 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
CRP was more frequently raised at diagnosis in CD than UC (63% versus 22%, P < 0.0001).
|
25636121 |
2015 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
CRP at biologic introduction and age at CD onset predicted LOR.
|
28422861 |
2017 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
CRP and Fcal may be accurate in prediction of MH of CD when MH is evaluated throughout the entire intestine including the small bowel.
|
30873890 |
2019 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
C-reactive protein was independently associated with ileal CD but non-signficant in a multivariate model.
|
31769537 |
2020 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
A high IL-6 concentration on POD 1 is independently associated with the occurrence of postoperative IASCs in patients undergoing elective surgery for CD and could allow for earlier diagnosis and earlier intervention for IASCs compared with C-reactive protein.
|
29912382 |
2018 |
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A univariate analysis demonstrated that early ER was significantly correlated with history of prior intestinal resections for CD (p = 0.005), low preoperative albumin levels (p = 0.035), and excessive perioperative inflammation (i.e., high C-reactive protein levels in both preoperative and postoperative periods; p = 0.034).
|
30602165 |
2019 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Absence of relationship between CDAI or CRP and infliximab exposure calls for objective Crohn's disease activity measures for the evaluation of treatment effects at treatment failure.
|
30601426 |
2018 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Additionally, IRF1 was correlated with high-sensitivity C-reactive protein, erythrocyte sedimentation rate, Crohn's disease activity index, Crohn's disease endoscopic index of severity, and simple endoscopic score for Crohn's disease in Crohn's disease and with high-sensitivity C-reactive protein, erythrocyte sedimentation rate, Mayo score, Baron score, modified Baron score, Rachmilewitz score, ulcerative colitis endoscopic index of severity, ulcerative colitis colonoscopic index of severity, and disease duration in ulcerative colitis.
|
25208103 |
2014 |
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Additionally, lncRNA ANRIL expression was negatively associated with Crohn's disease activity index (P = 0.002), C-reactive protein (P < 0.001) and erythrocyte sedimentation rate (P = 0.001), and associated with tumor necrosis factor-α (P < 0.001), IL-17 (P < 0.001) and interferon gamma messenger RNA levels (P = 0.004) but positively associated with IL-10 messenger RNA level (P = 0.002).
|
30665494 |
2019 |
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Allele distribution (odds ratio, 12.9; CI, 1.18-140.81, P < 0.001) and CRP serum levels (odds ratio, 1.020; CI, 1.00-1.04, P < 0.001) were independently associated with CD complications.
|
16707968 |
2006 |
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
At week 44 of the maintenance study (52 weeks after treatment began), patients were evaluated for the primary endpoint of clinical remission (defined as a CD activity index score below 150 points), endoscopic markers of efficacy, and serum level of C-reactive protein.
|
29409871 |
2018 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
BAE findings showed that FC was more accurate for predicting endoscopic remission in CD than C-reactive protein, albumin, white blood cell count, and platelet count.
|
28817462 |
2017 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Before treatment and 10 weeks later we collected: clinical activity [Harvey Bradshaw Index (HBI) and Crohn's-Disease-Activity-Index (CDAI)], serum C-reactive protein (CRP) and fecal calprotectin, and BSFS (1-7) and a 100-mm VAS based on a 7-day diary.
|
31651651 |
2020 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Biomarkers of intestinal inflammation, such as faecal calprotectin and C-reactive protein, have been recommended for monitoring patients with Crohn's disease, but whether their use in treatment decisions improves outcomes is unknown.
|
29096949 |
2018 |
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study.
|
18566104 |
2008 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
CLE<sup>+</sup> patients showed an increased incidence of medical treatment escalation (P < .001; relative risk [RR] = 3.27) and transmural lesions (P = .025; RR = 1.70), whereas patients with CRP ≥5 mg/L had increased CD-related hospitalization and surgery (P = .020, RR = 2.71) at 1-year follow-up.
|
29108979 |
2018 |
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Clinical and biological response evaluation was based on the Crohn's Disease Activity Index score and C-reactive protein level evolutions, respectively.
|
17001292 |
2006 |
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Clinical and biological responses were assessed by the Crohn's disease activity index and C-reactive protein levels, respectively.
|
23358932 |
2013 |
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Clinical disease activity was assessed by Crohn's disease activity index and C-reactive protein.
|
29348747 |
2017 |